Bavarian Nordic is making “every effort” to satisfy demand for its monkeypox vaccine, the only approved shot against the rapidly spreading disease, as countries grapple with severely limited supplies.
The Danish biotech company’s chief executive Paul Chaplin said on Wednesday the outbreak was “unprecedented”, as the company released its first-half results.
“We are making every effort to meet the initial worldwide demand for our monkeypox vaccine and are working diligently to further expand our manufacturing capacity through additional scale-up activities and partnerships,” he said.
您已閱讀24%（588字），剩余76%（1832字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。